OBJECTIVE: This open-label, randomized controlled trial investigated the effects of cilnidipine, an L/N-type calcium channel blocker (CCB), in patients with chronic kidney disease (CKD). METHODS: Sixty patients with CKD and well-controlled hypertension being treated with a renin—angiotensin system (RAS) inhibitor and an L-type CCB (L-CCB) were randomly assigned either to switch from the L-CCB to cilnidipine after a 4-week observation period or to continue with L-CCB treatment. Blood pressure, heart rate and renal function were monitored for 12 months. Data were available for analysis from 50 patients: 24 from the cilnidipine group and 26 from the L-CCB group. RESULTS: Blood pressure was well controlled in both groups. After 12 months, proteinuria and heart rate were significantly decreased in the cilnidipine group, but proteinuria increased and heart rate remained unchanged in the L-CCB group. There was a significant positive correlation between the percentage changes in proteinuria and heart rate. CONCLUSIONS: Cilnidipine has antihypertensive effects equivalent to those of L-CCBs. In patients with CKD, proteinuria can be decreased by switching from an L-CCB to cilnidipine, thereby improving renal function.
WrightJTJrBakrisGGreeneT: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA2002; 288: 2421–2431.
2.
JafarTHStarkPCSchmidCH: Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med2003; 139: 244–252.
3.
SarafidisPAKhoslaNBakrisGL: Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis2007; 49: 12–26.
4.
ChobanianAVBakrisGLBlackHR: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA2003; 289: 2560–2572.
5.
OgiharaTKikuchiKMatsuokaH: The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res2009; 32: 3–107.
6.
MatersonBJRedaDJCushmanWC: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med1993; 328: 914–921.
7.
LewisEJHunsickerLGClarkeWR: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med2001; 345: 851–860.
8.
Shiga Microalbuminuria Reduction Trial (SMART) Group, Uzu T, Sawaguchi M, et al: Impact of renin—angiotensin system inhibition on microalbuminuria in type 2 diabetes: A post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART). Hypertens Res2008; 31: 1171–1176.
9.
HayashiKWakinoSSuganoN: Ca2+ channel subtypes and pharmacology in the kidney. Circ Res2007; 100: 342–353.
10.
FujiiSKameyamaKHosonoM: Effect of cilnidipine, a novel dihydropyridine Ca++-channel antagonist, on N-type Ca++ channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther1997; 280: 1184–1191.
11.
HosonoMFujiiSHirumaT: Inhibitory effect of cilnidipine on vascular sympathetic neurotransmission and subsequent vasoconstriction in spontaneously hypertensive rats. Jpn J Pharmacol1995; 69: 127–134.
12.
UneyamaHUchidaHYoshimotoR: Effects of a novel antihypertensive drug, cilnidipine, on catecholamine secretion from differentiated PC12 cells. Hypertension1998; 31: 1195–1199.
13.
HosonoMHirumaTWatanabeK: Inhibitory effect of cilnidipine on pressor response to acute cold stress in spontaneously hypertensive rats. Jpn J Pharmacol1995; 69: 119–125.
14.
TakedaSUeshibaHHattoriY: Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract1999; 44: 197–205.
15.
HoshideSKarioKIshikawaJ: Comparison of the effects of cilnidipine and amlodipine on ambulatory blood pressure. Hypertens Res2005; 28: 1003–1008.
16.
MinamiJIshimitsuTKawanoY: Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard. J Cardiovasc Pharmacol1998; 32: 331–336.
17.
TakaharaA: Cilnidipine: A new generation Ca2+ channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther2009; 27: 124–139.
18.
ZhouXOnoHOnoY: N- and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens2002; 20: 993–1000.
19.
KonnoYKimuraK: Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles. Int Heart J2008; 49: 723–732.
20.
The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet1997; 349: 1857–1863.
21.
Ruggenenti P, Perna A, Remuzzi G, for the GISEN Group Investigators: Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int2003; 63: 2254–2261.
22.
FujitaTAndoKNishimuraH: Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin—angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int2007; 72: 1543–1549.
23.
KatayamaKNomuraSIshikawaH: Comparison between valsartan and valsartan plus cilnidipine in type II diabetics with normo-and microalbuminuria. Kidney Int2006; 70: 151–156.
24.
MorimotoSYanoYMakiK: Renal and vascular protective effects of cilnidipine in patients with essential hypertension. J Hypertens2007; 25: 2178–2183.
25.
KojimaSShidaMYokoyamaH: Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res2004; 27: 379–385.
26.
RoseGWKannoYIkebukuroH: Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res2001; 24: 377–383.
27.
TsuchihashiTUenoMTominagaM: Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine. Clin Exp Hypertens2005; 27: 583–591.
28.
CockcroftDWGaultMH: Prediction of creatinine clearance from serum creatinine. Nephron1976; 16: 31–41.
29.
GinsbergJMChangBSMatareseRA: Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med1983; 309: 1543–1546.
30.
SchwabSJChristensenRLDoughertyK: Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med1987; 147: 943–944.
31.
GoASChertowGMFanD: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med2004; 351: 1296–1305.
32.
KeithDSNicholsGAGullionCM: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med2004; 164: 659–663.
33.
NinomiyaTKiyoharaYKuboM: Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int2005; 68: 228–236.
34.
IrieFIsoHSairenchiT: The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int2006; 69: 1264–1271.
35.
KarioK: Proposal of RAS-diuretic vs. RAS-calcium antagonist strategies in high-risk hypertension: insight from the 24-hour ambulatory blood pressure profile and central pressure. J Am Soc Hypertens2010; 4: 215–218.
36.
HollenbergNK: Impact of angiotensin II on the kidney: does an angiotensin II receptor blocker make sense?Am J Kidney Dis2000; 36 (suppl 1): S18–S23.
37.
NagahamaSNorimatsuTMakiT: The effect of combination therapy with an L/N-type Ca2+ channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: an observational study conducted in Japan. Hypertens Res2007; 30: 815–822.
38.
NeumannJLigtenbergGKleinIH: Sympathetic hyperactivity in hypertensive chronic kidney disease patients is reduced during standard treatment. Hypertension2007; 49: 506–510.
39.
KondaTEnomotoAMatsushitaJ: The N-and L-type calcium channel blocker cilnidipine suppresses renal injury in Dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol2005; 101: 1–13.
40.
KondaTEnomotoATakaharaA: Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol Pharm Bull2006; 29: 933–937.
41.
SugiuraTImaiEMoriyamaT: Calcium channel blockers inhibit proliferation and matrix production in rat mesangial cells: possible mechanism of suppression of AP-1 and CREB activities. Nephron2000; 85: 71–80.
